Fresenius Kabi Oncology Ltd, (formerly known as Dabur Pharma Ltd) a Rs. 490 crore plus pharma major, has decided to delist its shares from BSE and NSE as its holding company, Fresenius Kabi (Singapore) Pte Ltd (Acquirer), is set to acquire remaining 19 per cent equity share capital (30,063,255 shares) of Re 1 each from public shareholders at a price of Rs. 130 per share. The offer will commence from October 15, 2013 and close on October 22, 2013. DSP Merrill Lynch Ltd is the 'Manager to the Delisting Offer'.
If the Delisting Offer is successful in terms of Section 10 of this Public Announcement, the Acquirer will apply for delisting of the shares from the stock exchanges where the shares are currently listed, in accordance with the Delisting Regulations. The Acquirer is the promoter of the company and holds 81 per cent of the fully paid-up equity share capital of the company.
The Acquirer vide a letter dated April 16, 2013 notified the company of its intention to commence the Delisting Offer and requested that the board of directors of the company convene a meeting of the shareholders of the company seeking the approval of the shareholders to delist the shares from the Stock Exchanges.
The board of directors of the company in its meeting held on April 17, 2013, sought the approval of the shareholders for the delisting offer by way of special resolution through postal ballot.